Kornimate/medical-research-clean huggingface dataset:
the effects of pelvic floor muscle training combined with otago exercises in elderly people with incontinence

Conditions: Urinary Incontinence; Pelvic Floor Muscle Weakness; Muscle Weakness

Summary: pelvic floor muscle weakness is one of the most important causes of incontinence. there are many studies supporting that pelvic floor muscle training prevents incontinence and reduces symptom severity, and with a level of evidence, it is among the first in the conservative treatment of incontinence. functional status and balance problems are common in elderly people with incontinence, and it is known that functional type incontinence is common. elderly people with incontinence most often fall while trying to get to the toilet. balance exercises are recommended for falls and balance problems. the aim of this study is to examine whether pelvic floor muscle training (pfmt) combined with otago exercises is effective on symptoms, balance and functional status in elderly people with ui living in nursing homes, compared to pfmt alone.

the research was conducted on participants over the age of 65 with urinary incontinence living in a nursing home. after these participants were informed about the content of the study, a signed informed consent form will be obtained. this study is an assessor-blinded, randomized controlled trial. participants with incontinence aged 65 and over living in a nursig home were randomly assigned to intervention (ig) and control group (cg). the intervention group attended an exercise program that included otago exercises combined with pelvic floor muscle training (pfmt). the control group was included in the pfmt program with different positions. duration of exercise for both groups was 45-60 minutes per session three times a week for 12 weeks. incontinence symptoms and severity (pelvic floor distress inventory-20, bladder diary), pfm muscle function (superficial electromyography), balance (berg balance scale), functional status (senior fitness test) and fear of falling (falls efficacy scale) was measured at baseline and after the intervention.

Eligibility criteria:
inclusion criteria: 1. having signed the informed volunteer consent form 2. being 65 years or older 3. having urinary incontinence 4. ability to walk unaided and not use any walking aids exclusion criteria: 1. having severe walking and balance problems 2. severe cognitive impairment (mini mental state assessment test score below 23) 3. having a serious neurological problem 4. having serious heart diseases 5. having a genito-urinary infection 6. having pelvic organ prolapse 7. six months ago he received medication for incontinence 8. having had incontinence and abdominal surgery 9. having metastatic cancer 10. having any vision problems

Keywords: urinary incontinence pelvic floor muscle training elektromyography balance exercises otago exercises
occult obscure gastrointestinal bleeding

Conditions: Gastrointestinal Bleeding

Summary: to test the activity of a polyglucosamine (pg) together with a standard management protocol (sm) on the occult and obscure gastrointestinal bleeding (ogib) and the clinical symptoms in patients suffering from colonic diverticulitis (cd).

the trial was conducted in a single center and subjects were participating to the san valentino vascular screening project (svvsp). sixty patients with history of colonic diverticulitis (cd) and occult obscure gastrointestinal bleeding (ogib) were recruited. all subjects were following a standard management (sm) protocol consisting of diet and lifestyle modifications, and were freely choosing to be treated with polyglucosamine (pg) or to follow the sm only. two groups of 30 cases each were formed and followed for 3 months. diet was controlled three times (baseline and during the first and third month), through the food intake assessment (fia) which consisted of the weekly analysis of 25 different servings (e,g fruits, vegetables, pulses, first dish, meat, processed meat, cheese). the lifestyle modification consisted of physical exercise (9 met (metabolic equivalents) -h/week of brisk walking) and oral hygiene. the main variable was ogib, that was measured using hemoccult sensa fecal occult blood procedure. ancillary variables where the hs-crp (high sensitivity c ractive protein) and the daily gastrointestinal discomfort (gid) measured thorough a visual analogue scale (vas) from 0 to 10. all variables were taken at baseline, after one and three months with the exception of gid that was measured also after one week of treatment.

Eligibility criteria:
inclusion criteria: * subjects aged between 55 to 65 years (males and females). * cd diagnosis. * dica (diverticular inflammation and complication assessment) class dica 2 or dica 3. * ogib positive to hemoccult sensa fecal occult blood procedure. exclusion criteria: * subjects with class dica \> 3. * therapy with mesalazine antibiotics and probiotics. * cancer of any type (a part from benign polyposis), * alcoholism. * parkinsonism. * alzheimer's disease. * severe depression. * drug addiction.
angioshield first-in-human study to demonstrate the preliminary safety and efficacy

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to determine whether or not the angioshield device can be safely applied to support saphenous vein grafts used in standard coronary bypass surgery.

\\this is a first in human study which is intended to determine if a larger pivotal study is justified.

Eligibility criteria:
inclusion criteria: subject will be eligible for inclusion in the investigation if he/she: * is between the ages of 18 and 80 years of age, inclusive * requires coronary atery bypass graft (cabg) surgery with minimum of one svg used to bypass a stenosis in the right coronary, the circumflex, a diagonal, or an obtuse marginal artery, due to atherosclerotic coronary artery disease * is able to give their informed written consent * is willing and able to complete all follow-up visits and procedures exclusion criteria: subject will be excluded from participation in the investigation if he/she: * is currently enrolled in another clinical investigation * is unable to tolerate or comply with required post-surgical medications or imaging (e.g., anticoagulation regimen; or known allergy to contrast agent) * is or may be pregnant or is lactating, or plans to become pregnant in the next 12 months * shows a presence of hypercoagulable state or history of idiopathic venous or arterial thrombosis * has had an acute mi within the last 21 days * has had a previous cabg * requires emergency surgery * has a left ejection fraction (lef) less than 20% * has a target vessel stenosis of less than 70% * has a transmural infarct of the target artery territory * currently requiring dialysis * is having concomitant-surgery of any kind * has varicose veins * has had previous saphenectomy

Keywords: cabg intimal hyperplasia atherosclerosis myocardial infarction
rheos® diastolic heart failure trial

Conditions: Diastolic Heart Failure

Summary: the cvrx® rheos® diastolic heart failure trial is a prospective, randomized, double blind trial with up to 60 subjects conducted at up to five centers in europe. all subjects will be followed up to one year post implant.


Eligibility criteria:
inclusion criteria: * be at least 21 years of age. * have bilateral carotid bifurcations that are below the level of the mandible. * have a left ventricular ejection fraction ≥ 45%. * clinical heart failure with elevated bnp or nt-pro-bnp. exclusion criteria: * history of or suspected baroreflex failure or autonomic neuropathy. * history of symptomatic bradyarrhythmias, pericardial constriction, infiltrative cardiomyopathy, cardiac valvular disease. * organ or hematologic transplant. * history of prior surgery, radiation, or stent placement in carotid sinus region. * history of severe chronic kidney disease. * life expectancy to less than one year.

Keywords: diastolic heart failure cardiac dysfunction heart failure
portable neuromodulation stimulator registry for people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the registry will be designed to gather information over 3 years. this important health economic information will help to establish the value of the pons device on key therapeutic outcomes. these outcomes will include: disease-associated injury risks (i.e., falls), onset of new comorbidities and/or worsening/improvement of existing medical condition(s) (other than gait deficit/impairment), need for new pharmacological/non-pharmacological intervention or increase/decrease of ongoing pharmacotherapy or other non-pharmacological intervention, increase/decrease of in patient/outpatient hospital and/or office visits or stays, side effects. by participation in the registry, patients and physicians will be providing helius with access to information about medical history, medical diagnoses, clinical symptom presentations, vocational information, medications, pharmacologic and non-pharmacologic prescriptions, hospitalization and healthcare visits, and any reported therapy's adverse events.


Eligibility criteria:
inclusion criteria: none * diagnosis of gait deficit due to ms exclusion criteria: none * unable to ambulate with or without an assisting device

Keywords: gait deficit, pons
prognostic value of aims65 score to predict outcome in patients with acute upper gastrointestinal bleeding

Conditions: Patients With Acute Upper Gastrointestinal Bleeding

Summary: prognostic value of aims65 score to predict outcome in patients with acute upper gastrointestinal bleeding

gastrointestinal (gi) bleeding is one of the most important disease presentations in the emergency department. the course of the disease ranges from a self-limiting process to a life-threatening condition that requires emergency intervention. evaluation of severity and the need for endoscopic hemostasis are matters of immediate decision. several prognostic scoring systems have been used to predict outcomes of upper gi bleeding ,such as the rockall score, glasgow-blatchford score (gbs), and the aims65 score, among which aims65 is relatively easy to remember and simple to calculate by using parameters routinely available in the ed and importantly does not require endoscopic variables for calculation.. the aims65 score consists of five factors: (i)albumin (1 point for value less than 3.0 g/dl (30 g/l)). (ii)inr (1 point for value greater than 1.5) . (iii)altered mental status (1 point given if glasgow coma score was less than 14 or if disorientation, lethargy, stupor, or coma was seen) (iv)systolic blood pressure (1 point for value less than 90 mmhg). (v)age (1 point for value greater than 65 years). aims65 score \>1: high risk patients. aims65 score \>2: consider icu management and an urgent endoscopy following adequate volume resuscitation, while aims65 score of 0 can be considered for outpatient management. aims65 score is a simple non-endoscopic risk score that can be applied in patients of acute upper gastrointestinal bleeding to risk stratify and to predict in-patient mortality, the need for blood transfusion, endoscopic therapy or icu admission. in a comparative study of aims65 score and gbs ,they found that the aims65 score was superior in predicting inpatient mortality from ugib, while the gbs was superior for predicting the need for blood transfusion. both scores were similar in predicting the composite clinical endpoint .

Eligibility criteria:
inclusion criteria: * o patients above 18 years of age. * patients with acute ugib presenting within 24 hours of hemorrhage onset. * endoscopic evaluation done after hospital admission. exclusion criteria: * o patients denying for consent. * patients with late presentation (\>24 hours) after ugib onset.
incidence, risk factors, severity and prognosis of necrotizing enterocolitis in turkey

Conditions: Necrotizing Enterocolitis

Summary: necrotizing enterocolitis (nec) is a gastrointestinal system disease characterized by inflammatory necrosis of the intestine mainly seen in premature infants, and continues to be an important cause of mortality and morbidity in neonatal intensive care units all over the world. although it is more common in premature infants, it is also seen in term babies when the intestine is ischemic. although the major problem in premature babies is the immaturity of the intestine, many factors contributing to immaturity play a role in the pathogenesis of nec.

necrotizing enterocolitis (nec) is a gastrointestinal system disease characterized by inflammatory necrosis of the intestine mainly seen in premature infants, and continues to be an important cause of mortality and morbidity in neonatal intensive care units all over the world. although it is more common in premature infants, it is also seen in term babies when the intestine is ischemic. although the major problem in premature babies is the immaturity of the intestine, many factors contributing to immaturity play a role in the pathogenesis of nec. with this study project, which is planned as a national multicenter prospective study, the incidence of necrotizing enterocolitis in newborn infants born in neonatal intensive care units in our country and the risk factors associated with the nec, especially the detailed feeding history of the patient (when the first feeding is nourished, antibiotics and other treatments that are being used). most epidemiological data such as the most common stage of the disease, treatment, prognosis, comparison with the data of other countries will provide important information for the neonatal health of our country. the aim of this study was to determine the factors affecting the emergence of nec in neonatal intensive care units and to determine the frequency of nec. study hypothesis: delayed enteral feeding, intensive use of antibiotics and nutrients other than breast milk increase the incidence of necrotizing enterocolitis.

Eligibility criteria:
inclusion criteria: * newborns diagnosed with nec in neonatal intensive care units exclusion criteria: * major congenital anomaly, * congenital heart disease (except for atrial septal defect, ventricular septal defect, patent ductus arteriosus) * chromosomal anomaly * inherited metabolic disease * hypoxic ischemic encephalopathy * newborns who died within the first 48 hours of life

Keywords: neonate newborn premature necrotizing enterocolitis neonatal intensive care unit infant incidence risk factors turkey
early recovery after "wedge resection" surgery to remove lung mestastasis secondary to bone cancer.

Conditions: Metastasis Lung; Bone Neoplasm

Summary: after "wedge resection" surgery, the physiotherapy programs proposed in the literature are heterogeneous and there are few data on the outcomes of such treatments in an oncological population for bone cancer. the aim of the study is to describe the early rehabilitation process after wedge resection surgery secondary to bone tumor pulmonary mestasasis, highlightining the possible functional recovery in the short and medium term after surgery and indentifying the possible prognostic factors.

in italy, the incidence of primary bone tumors is around 0.8-1 case per 100,000 inhabitants, therefore an estimated 500 new cases of primary malignant bone tumors are estimated each year, affecting more frequently in children and young people. the presence of pulmonary metastasis occurs in 30% of the population with bone cancer and is the most common site of metastasis. where possible, the elective treatment of lung metastases is ablative surgery and the wedge resection technique is also commonly used in the event of repeated metastasis over time. pulmonary wedge resection surgery does not follow the anatomical limits of the lung but it is customized according to the metastatic area to be removed, thus differentiating itself from lobectomies and other thoracotomy surgical techniques. the trend of vital capacity (cv) and forced expiratory volume in 1s (fev1), after wedge resection surgery, significantly decrease at 3 months compared to the preoperative evaluation, while at 12 months the cv returns to values close to the preoperative ones and fev1 remains significantly lower. rehabilitation treatment is part of the multidisciplinary approach for this type of patient in order to prevent post-surgical respiratory complications (ppc) and shoulder girdle dysfunctions, in the treatment of pain and in the recovery of respiratory volumes. several authors, describing the physiotherapy treatment techniques, include breathing exercises (active cycle breathing techniques), early mobilization exercises for the lower limbs and the use of volume incentives. the physiotherapy treatment programs proposed in the literature are heterogeneous and there are no data on the feasibility of such treatments in an oncological population for bone cancer. patients are enrolled consecutively in a ward of an italian hospital specialized in bone tumor surgery.

Eligibility criteria:
inclusion criteria: * over 12 years of age * ablative thoracic surgery for metastases localized to the lung and / or chest wall for primary bone cancer * must be able to perform the "one minute sit-to-stand" test in the preoperative physiotherapy evaluation exclusion criteria: * ablative thoracic surgery for a diagnosis different from that of lung metastases

Keywords: pulmonary rehabilitation wedge resection early recovery
sofosbuvir/pegylated-interferon plus ribavirin with hcv genotype 4

Conditions: Hepatitis C Virus Infection

Summary: this study aims to assess the efficacy and safety of sofosbuvir (sof) with pegylated interferon (peginf)/ribavirin (rbv) for chronic hcv gt4 participants

between march 2015 and november 2015, 99 participants (59 naïve and 40 experienced) infected with hcv gt4 were enrolled in the study. eligible participants received daily oral 400 mg sof ( (sovaldi, gilead sciences, inc., usa), rbv (copegus, roche, europe) based on body weight: \< 75 kg, 1000 mg; ≥75 kg, 1200 mg), the dose modified according to participants tolerability, plus 180 μg peginfα-2 once weekly for 12 weeks. experienced participants included participants with a prior relapse or a null response to peginf/rbv therapy.

Eligibility criteria:
inclusion criteria: the study population consisted of treatment-naïve and treatment-experienced adults patients aged 20-65 with hcv rna level \> 10,000 iu/ml. experienced participants included those with a prior relapse or a null response to peginf/rbv therapy. - exclusion criteria:participants with one or more of * hcv coinfected with hepatitis b virus (hbv) * human immunodeficiency virus (hiv) * had any liver disease other than chronic hcv gt4 infection. * had a history of liver decompensation * serum a-fetoprotein (afp) \> 100 ng/ml * evidence of hepatocellular carcinoma * major severe illness such as respiratory, renal, heart failure or autoimmune disease * non-compliance with treatment.

Keywords: hcv genotype 4 sofosbuvir peg-interferon α-2 ribavirin egyptian patients experinced naive
pharmacokinetics of dabigatran etexilate (pradaxa®) during haemodialysis

Conditions: Cardiovascular Diseases; Kidney Failure, Chronic

Summary: the current study will allow the assessment of pharmacokinetics, pharmacodynamics, elimination rate and clearance of dabigatran etexilate during and following haemodialysis in esrd patients.


Eligibility criteria:
inclusion criteria: * end stage renally disease (esrd), undergoing haemodialysis * esrd patients in relatively good health * age 21 - 60 years inclusive * signed and dated written informed consent prior to admission to the study exclusion criteria: * clinically relevant laboratory or physical examination abnormalities (except for renal function tests or deviation of clinical laboratory values) that are related to renal impairment * moderate and severe concurrent liver function impairment * surgery of gastrointestinal tract (except appendectomy or herniotomy) or evidence of significant gastrointestinal motility problems * recent or contemplated diagnostic or therapeutic procedures with potential for uncontrollable bleeding * intake of medication, which influences the blood clotting * subjects not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions * for women with childbearing potential: no reliable contraception * participation in another trial with an investigational drug (\<2 months prior to administration or during trial) * scheduled to receive a donor kidney transplant during the course of the study
study to investigate the effectiveness of a topical cosmetic formulation da-otc-002

Conditions: Hair Diseases; Alopecia; Hair Loss

Summary: the primary objective of the study was to assess the efficacy of da-otc-002 as a topical cosmetic hair treatment. the investigators conducted a prospective, institution-level, interventional, single-blinded, placebo-controlled investigation to assess the efficacy of a combination an alpha-1 agonist and a taar receptor agonist (da-otc-002) as a topical cosmetic hair treatment.

76 female subjects were included in the study. subjects were otherwise healthy females, aged 18 years are older, and had ample hair on the scalp to allow application of test article. subjects with an interfering dermatologic disease or procedure, who were pregnant, lactating, or planning to become pregnant during the study, had experienced a clinically important medical event within 90 days of the visit, who were actively treated for hypertension, or had known allergies to any excipient in da-otc-002 were excluded from the study. this study was conducted in compliance with good clinical practice, including the archival of essential documents. all subjects gave informed consent during the study enrollment.

Eligibility criteria:
inclusion criteria: * females age 18 or older * willing and able to apply the treatment as directed, comply with study * subject has ample hair on the scalp to allow application of test article * otherwise healthy. * able to give informed consent exclusion criteria: * a medical history that may interfere with study objectives. * subjects with any dermatologic disease in the treatment area. * women who are pregnant, lactating, or planning to become pregnant during the study period. * subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc). * subjects who are actively treated for hypertension. * subjects who have known allergies to any excipient in da-otc-002 * subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation. * subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation. * subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation. * subject is unable to provide consent or make the allotted clinical visits.